{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:14:08Z","timestamp":1781943248939,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd005197.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T00:00:00Z","timestamp":1289347200000}}],"reference-count":163,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005197.pub3","type":"journal-article","created":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T22:40:51Z","timestamp":1288651251000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams"],"prefix":"10.1002","volume":"2015","author":[{"given":"Mical","family":"Paul","sequence":"first","affiliation":[{"name":"Rambam Health Care Campus; Division of Infectious Diseases; Ha-aliya 8 St Haifa Israel 33705"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Department of Medicine E; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf","family":"Bivas","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Department of Medicine E; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Fraser","sequence":"additional","affiliation":[{"name":"University of Bristol, Oakfield House; MRC Integrative Epidemiology Unit at the University of Bristol; Oakfield Road Bristol UK BS8 2BN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Leibovici","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Department of Medicine E; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,10]]},"reference":[{"issue":"3 Pt 2","key":"10.1002\/14651858.CD005197.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0002-9343(88)90140-4","article-title":"Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients","volume":"84","author":"Anaissie","year":"1988","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0002|cit2","unstructured":"Aoun M Boogaerts MA Bosly AJ Schots H A multicenter, randomized, prospective, comparative study of cefepime plus vancomycin versus ceftazidime plus vancomycin as empiric therapy in the treatment of febrile episodes in granulocytopenic patients with hematological malignancies Joint clinical\/statistical review of NDA 50,679\/SE1-002: study AI411-198 1997 122 32"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-642-60443-0_13","article-title":"Cefepime versus Ceftazidime as empiric therapy of febrile episodes in neutropenic patients","volume-title":"Febrile neutropenia","author":"Breen","year":"1997"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0004|cit4","unstructured":"Aparicio J Gomez-Aldaravi L Pastor M Munarriz B Gomez J Maestu Randomized comparison of Ceftazidime and Imipenem in oncologic patients with neutropenic fever Oncologia. IV Congreso Nacional de la SEOM 1993 248"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0005|cit5","first-page":"122","article-title":"Ceftazidime versus imipenem as initial monotherapy in oncologic patients with fever and neutropenia: preliminary results of a randomized trial","volume":"10","author":"Aparicio","year":"1993","journal-title":"Neoplasia"},{"issue":"10","key":"10.1002\/14651858.CD005197.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/0959-8049(96)00188-8","article-title":"Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients","volume":"32A","author":"Aparicio","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0007|cit7","unstructured":"Bickers J Gumbart C Cavalier J Vial R Ostroske DR Veith R A prospective randomized trial of cefoperazone plus sulbactam versus imipenem-cilastatin in febrile neutropenic patients Clinical Research 1990 991A"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0008|cit8","unstructured":"Bickers J Gumbart C Vial R A prospective randomized trial of cefoperazone plus sulbactam versus imipenem-cilastatin in febrile, neutropenic patients Program and abstracts of the 18th international congress of chemotherapy Stockholm 1993 217"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/jac\/42.4.511","article-title":"Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer)","volume":"42","author":"Biron","year":"1998","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Biron P Fuhrmann C Kheder K Viens P Lefebvre D Beal J Cefepime (CEP) vs Imipenem-cilastatin (IMP) as empiric monotherapy in 400 febrile patients with short duration neutropenia 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Ontario, Canada 1997","DOI":"10.1093\/jac\/42.4.511"},{"issue":"Abs No 74","key":"10.1002\/14651858.CD005197.pub3-BIB0011|cit11","first-page":"323","article-title":"Cepemine (CEP) vs Imipenem-cilastatin (IMP) as empiric monotherapy in 400 febrile patients with short duration neutropenia","volume":"6 Suppi","author":"Fuhrmann","year":"1998","journal-title":"Supportive Care in Cancer"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/1097-0142(19900101)65:1<9::AID-CNCR2820650105>3.0.CO;2-C","article-title":"Beta-lactam regimens for the febrile neutropenic patient","volume":"65","author":"Bodey","year":"1990","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD005197.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/BF01691147","article-title":"Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients","volume":"15","author":"Bodey","year":"1996","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005197.pub3-BIB0014|cit14","first-page":"A44","article-title":"Cefepime (CEFP) versus piperacillin\/tazobactam (PIP\/TAZ) as initial antimicrobial therapy in febrile granulocytopenic patients","volume":"73","author":"Bohme","year":"1996","journal-title":"Annals of Hematology"},{"issue":"7","key":"10.1002\/14651858.CD005197.pub3-BIB0015|cit15","first-page":"324","article-title":"Piperacillin\/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study","volume":"3","author":"Bohme","year":"1998","journal-title":"European Journal of Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/jac\/36.1.185","article-title":"Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients","volume":"36","author":"Boogaerts","year":"1995","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0017|cit17","unstructured":"De-Pauw B Donnely P Boogaerts MA Mesidagh N Machin SJ Goldstone AH Meropenem or ceftazidime empiric therapy for febrile neutropenic adults 32nd Intersciense Confernce on Antimicrobial Agents and Chemotherapy Anaheim, California, USA 1992"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0018|cit18","first-page":"34","article-title":"Empiric monotherapy in neutropenia: a realistic goal?","volume":"96","author":"Favero","year":"1995","journal-title":"Scandinavian journal of infectious diseases. Supplementum"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0019|cit19","unstructured":"Bow EJ Noskin GA Schwarer AP Laverdiere M Vesole DH Efficacy of Piperacillin\/Tazobactam as Initial Empiric Therapy of Febrile Neutropenia in Patients with Hematologic Malignancy 45th Annual Meeting of the Americal Society of Hematology San Diego 2003 Abstract no. 1000"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1086\/505393","article-title":"A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies","volume":"43","author":"Bow","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0021|cit21","unstructured":"Bow EJ Schwarer AP Laverdiere M Segal BH Anaissie E Efficacy of Piperacillin\/Tazobactam as Initial Empiric Therapy of Febrile Neutropenia in Patients with Hematologic Malignancy 43th Interscience conferemce on antimicrobials agents and chemotherapy Chicago American Society for Microbiology 2003 Abstract no. L-114"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0022|cit22","unstructured":"Noskin GA Vesole D Szer J Sanche S McCarthy AE Annual Meeting of the Infectious Diseases Society of America San Diego 2003 Abstract no. 373"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-642-60443-0_13","article-title":"Cefepime versus Ceftazidime as empiric therapy of febrile episodes in neutropenic patients","volume-title":"Febrile neutropenia","author":"Breen","year":"1997"},{"issue":"9","key":"10.1002\/14651858.CD005197.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1345\/aph.10001","article-title":"Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer","volume":"34","author":"Chandrasekar","year":"2000","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0025|cit25","unstructured":"Hathorn J Chandrasakar P Baird I Arnow P Waskin A Double-blind Comparison of Cefepime vs Ceftazidime to Treat Febrile Neutropenia 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0026|cit26","unstructured":"Hathorn JW Chandrasekar PH Baird I Arnow P Velasquez W Heimenz J A double-blind randomized trial of cefepime versus ceftazidime fort the empirical treatment of febrile episodes in neutropenic cancer patients Joint clinical\/statistical review of NDA 50,679\/SE1-002: study AI411-204 1997 26 50"},{"issue":"8","key":"10.1002\/14651858.CD005197.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/00365540410017590","article-title":"A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies","volume":"36","author":"Cherif","year":"2004","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Cherif H Engervall P Bjorkholm M Kalin M Comparison of cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies: a prospective, randomised, multicentre study [abstract] 8th Congress of the European Hematology Association 2003 Lyon, France 2003","DOI":"10.1080\/00365540410017590"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00006454-200203000-00009","article-title":"Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer","volume":"21","author":"Chuang","year":"2002","journal-title":"Pediatric Infectious Diseases Journal"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/08880010500506370","article-title":"Monotherapy with piperacillin\/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison","volume":"23","author":"Corapcioglu","year":"2006","journal-title":"Pediatric Hematology and Oncology"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0031|cit31","unstructured":"Cornely OA Reichert D Buchheidt D Maschmeyer G Wilhelm M Schiel X Three-Armed Multicenter Randomized Study on the Empiric Treatment of neutropenic Fever in a High Risk Patient Population (PEG Study III). In ICAAC. Chicago; 2001 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago 2001 P446"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0032|cit32","first-page":"174","article-title":"Cefepime in the initial treatment of high-risk febrile neutropenic patients","volume":"13","author":"Maschmeyer","year":"2004","journal-title":"Chemotherapie Journal"},{"issue":"Abstr. 49","key":"10.1002\/14651858.CD005197.pub3-BIB0033|cit33","first-page":"157","article-title":"Initial empiric monotherapy with metropenem or ceftazidime in high risk cancer patients with febrile neutropenia","volume":"8 Suppl","author":"Pauw","year":"2000","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0034|cit34","unstructured":"Feld R De Pauw B Berman S Keating A Ho W Meropenem (MEM) Versus Ceftazidime (CAZ) for Initial Empiric Therapy in Cancer Patients with Febrile Neutropenia: Results of a Double-Blind, Randomized, Multicenter Trial 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, California 1999 722"},{"issue":"21","key":"10.1002\/14651858.CD005197.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1200\/JCO.2000.18.21.3690","article-title":"Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial","volume":"18","author":"Feld","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD005197.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0025-7753(01)71921-5","article-title":"Initial empiric therapy of febrile neutropenia with antibiotic monotherapy. Piperacillin\/tazobactam versus imipenem\/cilastatin (1994-1996)","volume":"116","author":"Figuera","year":"2001","journal-title":"Medicina Clinica"},{"issue":"6","key":"10.1002\/14651858.CD005197.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jac\/47.6.841","article-title":"Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer","volume":"47","author":"Fleischhack","year":"2001","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Abs No 48","key":"10.1002\/14651858.CD005197.pub3-BIB0038|cit38","first-page":"156","article-title":"A randomized comparison of ceftazidime versus meropenem in febrile neutropenia in pediatric cancer patients","volume":"8 suppl","author":"Hartmann","year":"2000","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0039|cit39","unstructured":"Fallon J Rubin M Hathorn J Callender D Albano E Walsh TJ Is a carbapenem as effective as a 3rd generation cephalosporin when used as monotherapy in the empiric treatment of the febrile neutropenic patient? 27th Interscience conference on Antimicrobial Agents Chemotherapy Washington DC 1987"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.1995.13.1.165","article-title":"Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem","volume":"13","author":"Freifeld","year":"1995","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0041|cit41","first-page":"111","article-title":"Monotherapy for empirical management of febrile neutropenic patients","volume":"9","author":"Rubin","year":"1990","journal-title":"National Cancer Institute Monographies"},{"issue":"3-4","key":"10.1002\/14651858.CD005197.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12288-008-0007-x","article-title":"Cefepime versus ceftazidime as empirical therapy for fever in neutropenic patients with haematological malignancies","volume":"23","author":"Ghalaut","year":"2007","journal-title":"Indian Journal of Hematology and Blood Transfusion"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-642-60443-0_13","article-title":"Cefepime versus Ceftazidime as empiric therapy of febrile episodes in neutropenic patients","volume-title":"Febrile neutropenia","author":"Breen","year":"1997"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0044|cit44","unstructured":"Glauser M Dekker AW Van Marwijkkooy M Palmblad J Wood M Harper P A multicenter comperative study of cefepime vs. ceftazidime as empiric therapy in the treatment of febrile episodes in neutropenic patients Joint clinical\/statistical review of NDA 50,679\/SE1-002: study AI411-189 1997 51 74"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.bmt.1705256","article-title":"Piperacillin\/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial","volume":"37","author":"Harter","year":"2006","journal-title":"Bone Marrow Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/mpo.1107","article-title":"Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors","volume":"36","author":"Kebudi","year":"2001","journal-title":"Medical and Pediatric Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/pbc.10442","article-title":"Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours","volume":"42","author":"Kutluk","year":"2004","journal-title":"Pediatric Blood & Cancer"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jjco\/hym151","article-title":"Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial","volume":"38","author":"Kwon","year":"2008","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD005197.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1128\/AAC.34.7.1336","article-title":"Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients","volume":"34","author":"Liang","year":"1990","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/00365549850160864","article-title":"Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime","volume":"30","author":"Lindblad","year":"1998","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00006454-200103000-00036","article-title":"Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia","volume":"20","author":"Mustafa","year":"2001","journal-title":"Pediatric Infectious Diseases Journal"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08880010500506867","article-title":"Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors","volume":"23","author":"Oguz","year":"2006","journal-title":"Pediatric Hematoly Oncology"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0053|cit53","unstructured":"Oppenheim BA Morgenstern GR Chang J Safety and efficacy of piperacillin\/tazobactam versus meropenem in the treatment of febrile neutropenia Proceeding of the 7th Conference of the Federation of Infection Societies 2000 page 67, 52"},{"issue":"8","key":"10.1002\/14651858.CD005197.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jjco\/hyq046","article-title":"Piperacillin-tazobactam Versus Carbapenem Therapy With andWithout Amikacin as Empirical Treatment of Febrile Neutropeniain Cancer Patients: Results of an Open Randomized Trialat a University Hospital","volume":"40","author":"Oztoprak","year":"2010","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD005197.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1386::AID-CNCR25>3.0.CO;2-X","article-title":"A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients","volume":"77","author":"Raad","year":"1996","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/cncr.11613","article-title":"Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime","volume":"98","author":"Raad","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-642-60443-0_13","article-title":"Cefepime versus Ceftazidime as empiric therapy of febrile episodes in neutropenic patients","volume-title":"Febrile Neutropenia","author":"Breen","year":"1997"},{"issue":"suppl 6A","key":"10.1002\/14651858.CD005197.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"83S","DOI":"10.1016\/S0002-9343(96)00113-1","article-title":"Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient","volume":"100","author":"Ramphal","year":"1996","journal-title":"The American Journal of Medicine"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0059|cit59","unstructured":"Ramphal R Haddow A McCracken GH A comparative study of cefepime vs. ceftazidime in the treatment of adult cancer patients with fever and neutropenia Joint clinical\/statistical review of NDA 50,679\/SE1-002: study AI411-131 1997 75 89"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2005.05608.x","article-title":"Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial","volume":"130","author":"Reich","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archinte.1992.00400140037010","article-title":"A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients","volume":"152","author":"Rolston","year":"1992","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005197.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01713054","article-title":"Empirical monotherapy with meropenem versus imipenem\/cilastatin for febrile episodes in neutropenic patients","volume":"24","author":"Shah","year":"1996","journal-title":"Infection"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0063|cit63","unstructured":"Shichmanter R Miller E Shtalrid M Landau Z Empiric antibiotic treatment of adults with neutropenic fever in a general internal medicine ward. In 14th European Congress of Clinical Microbiology and Infectious Diseases 14th European Congress of Clinical Microbiology and Infectious Diseases 2004"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ajh.10236","article-title":"Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study","volume":"71","author":"Tamura","year":"2002","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/pbc.22100","article-title":"Piperacillin\/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study","volume":"53","author":"Uygun","year":"2009","journal-title":"Pediatric Blood Cancer"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s002770050571","article-title":"Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients","volume":"79","author":"Vandercam","year":"2000","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0067|cit67","first-page":"EPUB","article-title":"Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia","volume":"EPUB","author":"Vural","journal-title":"Pediatrics International"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000007228","article-title":"A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients","volume":"45","author":"Wang","year":"1999","journal-title":"Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1086\/514578","article-title":"Randomized comparison of sulbactam\/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients","volume":"26","author":"Winston","year":"1998","journal-title":"Clinical Infectious Diseses"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0070|cit70","unstructured":"Bauduer F Cousin T Boulat O Attal M Molina L Rossi JF A Randomized Prospective Multicenter Trial of Cefpirome vs. Piperacillin-Tazobactam in Febrile Neutropenia 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California 1999 720"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/10428190109064594","article-title":"A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia","volume":"42","author":"Bauduer","year":"2001","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"S1582","DOI":"10.1093\/clinids\/11.Supplement_7.S1582","article-title":"Evolution of antibiotic therapy for infection in neutropenic patients: studies at MD Anderson Hospital","volume":"11 Suppl 7","author":"Bodey","year":"1989","journal-title":"Reviews of Infectious Diseases"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Borja J Herreras A Comparison of sulbactam\/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients Clinical Infectious Diseases 1999 406 07","DOI":"10.1086\/515109"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1128\/AAC.39.2.445","article-title":"Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"39","author":"Cometta","year":"1995","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1179\/joc.1996.8.5.375","article-title":"Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review","volume":"8","author":"Cometta","year":"1996","journal-title":"Journal of Chemotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0076|cit76","unstructured":"Cordonnier C Delmer A LeBlond V A multi-investigator comparative study of cefepime and ceftazidime, in combination with amikacin for the treatment of patients with fever and neutropenia NDA AI411-186"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/clinids\/24.1.41","article-title":"Cefepime\/amikacin versus ceftazidime\/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group","volume":"24","author":"Cordonnier","year":"1997","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00277-001-0392-9","article-title":"A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs. cefepime and gentamicin","volume":"81","author":"Cornely","year":"2002","journal-title":"Annals of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jac\/37.5.975","article-title":"A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients","volume":"37","author":"Deaney","year":"1996","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"11","key":"10.1002\/14651858.CD005197.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/00365540110076679","article-title":"Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study","volume":"33","author":"Erman","year":"2001","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0081|cit81","first-page":"157","article-title":"Randomized assessment of tienam vs. ceftazidime for the empirical therapy of suspected bacterial infections in neutropenic patients: preliminary results","volume":"77 Suppl 1","author":"Fanci","year":"1992","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0082|cit82","unstructured":"Gomez L Estrada C Gomez I Marquez M Dalmau D Estany C Cefepime Plus Amikacin versus Piperacillin-Tazobactam Plus Amikacin in the Treatment of Patients with Fever and Granulocytopenia 41st Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, DC, USA 2001 Abstract L-771, p. 445"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/32.suppl_B.175","article-title":"International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections","volume":"32 Suppl B","author":"Hoepelman","year":"1993","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/AAC.38.3.415","article-title":"Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome","volume":"38","author":"Kieft","year":"1994","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jac\/31.suppl_A.113","article-title":"Safety profile of piperacillin\/tazobactam in phase I and III clinical studies","volume":"31 Suppl A","author":"Kuye","year":"1993","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0086|cit86","unstructured":"Longree L De Bock R Meyer S A multicenter comparative study of cefepime plus amikacin vs. piperacillin-tazobactam plus amikacin in the empiric treatment of febrile episodes in neurtopenic cancer patients. CAPTA study group, Belgium 5th International Meeting on Febrile Neutropenia, Brussels"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0087|cit87","first-page":"15","article-title":"Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia","volume":"52","author":"Malik","year":"2002","journal-title":"Journal of the Pakistan Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0732-8893(97)00239-3","article-title":"Piperacillin\/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital","volume":"31","author":"Marra","year":"1998","journal-title":"Diagnostic microbiology and infectious disease"},{"issue":"11","key":"10.1002\/14651858.CD005197.pub3-BIB0089|cit89","first-page":"1194","article-title":"A randomized study of the empirical antibiotic therapy of the infections in neutropenic patients, affected by neoplastic diseases in paediatric age and under a fever attack","volume":"39","author":"Moroni","year":"1987","journal-title":"Giornale di malattie infettive e parassitarie"},{"issue":"suppl 5","key":"10.1002\/14651858.CD005197.pub3-BIB0090|cit90","first-page":"140","article-title":"Ceftazidime (CFZ) monotherapy as empirical initial treatment of febrile neutropenia cancer patients (Pts)","volume":"7","author":"Papachristodoulou","year":"1996","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF01964446","article-title":"Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins","volume":"10","author":"Rolston","year":"1991","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkf087","article-title":"Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial","volume":"50","author":"Sanz","year":"2002","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0093|cit93","unstructured":"Sanz MA Villal L Lahuerta JJ Rovira M Ribera JM Perez C Cefepime Plus Amikacin Versus Piperacillin\/Tazobactam Plus Amikacin for Initial Antibiotic Therapy in Hematological Patients with Febrile Neutropenia: Results of an Open, Randomized, Multicenter Trial Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 474"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3111\/200205135145","article-title":"A pharmacoeconomic evaluation of piperacillin\/tazobactam versus meropenem in the treatment of adult febrile neutropenia","volume":"5","author":"Smyth","year":"2002","journal-title":"Journal of Medical Economics"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"Sumitani Y Kobayashi Y Ceftazidime vs cefepime: comparison of two drugs as empirical therapeutic drugs for febrile neutropenia by Monte Carlo simulation method ECCMID 2007 Abstract 1722_873","DOI":"10.1016\/S0924-8579(07)71216-5"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0096|cit96","first-page":"1","article-title":"Comparison of ceftazidime versus sulbactam\/cefoperazone monotherapy as empiric therapy for febrile episodes in granulocytopenic children with cancer","volume":"36","author":"Tanindi","year":"1994","journal-title":"Bulletin of Gulhane Military Medical Academy"},{"issue":"suppl 5","key":"10.1002\/14651858.CD005197.pub3-BIB0097|cit97","first-page":"140","article-title":"Cefepime (C) monotherapy in febrile patients (PTS) with chemotherapy induced neutropenia (Preliminary results)","volume":"7","author":"Varthalitis","year":"1996","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0098|cit98","unstructured":"Zarostsky V Jaresko GS Holtom PD Piperacillin\/tazobactam use in febrile neutropenic patients: a meta-analysis 41st Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology 2001 446"},{"issue":"11","key":"10.1002\/14651858.CD005197.pub3-BIB0099|cit99","first-page":"439b (abstract","article-title":"A prospective randomized trial of meropenem versus imipenem\/cilastatin as monotherapy for neutropenic fever during early phase post stem cell transplantation","volume":"102","author":"Ma","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD005197.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ijid.2007.02.002","article-title":"Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia","volume":"11","author":"Baskaran","year":"2007","journal-title":"International Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01967060","article-title":"Fungal infections in cancer patients: an international autopsy survey","volume":"11","author":"Bodey","year":"1992","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2003.11.007","article-title":"In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae","volume":"49","author":"Burgess","year":"2004","journal-title":"Diagnostic Microbiology and Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"American Journal of Infectious Control"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0105|cit105","first-page":"1","article-title":"Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia","volume":"EPUB","author":"Chen","year":"2009","journal-title":"Epidemiology and Infection"},{"issue":"8","key":"10.1002\/14651858.CD005197.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","article-title":"Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy","volume":"115","author":"Chow","year":"1991","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0107|cit107","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1128\/AAC.01183-09","article-title":"Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa","volume":"54","author":"Crandon","year":"2010","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0109|cit109","article-title":"Infections in the immunocompromised Host: General Principles. In:","volume-title":"Mandell, Douglas and Bennet's Priciples and Practice of Infectious Diseases","author":"Pauw","year":"2000"},{"issue":"12","key":"10.1002\/14651858.CD005197.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"Pauw","year":"2008","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0111|cit111","unstructured":"De -bock R Cometta A Kern WV Aoun M Caballero D Engelhard D Incidence of Single Agent Gram-negative Bacteremias (SAGNB)in Neutropenic Cancer Patients (NCP) in EORTC-IATG Trials of Empirical Therapy for Febrile Neutropenia 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001 p. 445, abstract n\u00b0 L-773"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jac\/37.5.975","article-title":"A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients","volume":"37","author":"Deaney","year":"1996","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0113|cit113","unstructured":"International Immunocompromised Host Society European Conference on Infections in Leukaemic patients Guidelines for the Management of Bacterial, Fungal and Viral Infections http:\/\/www.ichs.org\/ecilslides.htm"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1200\/JCO.1998.16.3.1179","article-title":"Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis","volume":"16","author":"Engels","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0115|cit115","unstructured":"US Food Drug Administration Information for Healthcare Professionals: Cefepime Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm167254.htm"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/655131","article-title":"Meta-analysis of a possible signal of increased mortality associated with cefepime use","volume":"51","author":"Kim","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD005197.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1086\/344650","article-title":"Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society\/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies","volume":"35","author":"Feld","year":"2002","journal-title":"Clinicsl Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0732-8893(03)00114-7","article-title":"Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin\/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002)","volume":"47","author":"Fritsche","year":"2003","journal-title":"Diagnostic Microbiology and Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/AAC.40.5.1289","article-title":"Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins","volume":"40","author":"Fung-Tomc","year":"1996","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s005200000105","article-title":"Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis","volume":"8","author":"Furno","year":"2000","journal-title":"Supportive Care in Cancer"},{"issue":"12","key":"10.1002\/14651858.CD005197.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1469-0691.2002.00492.x","article-title":"Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation","volume":"8","author":"Goldstein","year":"2002","journal-title":"Clinical Microbiology and Infection"},{"issue":"7650","key":"10.1002\/14651858.CD005197.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD005197.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD005197.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","article-title":"The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting","volume":"118","author":"Ibrahim","year":"2000","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMra041359","article-title":"The new beta-lactamases","volume":"352","author":"Jacoby","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/infdis\/162.4.981","article-title":"Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy","volume":"162","author":"Johnson","year":"1990","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijid.2006.12.008","article-title":"Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade","volume":"11","author":"Kanafani","year":"2007","journal-title":"International Journal of Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD005197.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.45.9.2628-2630.2001","article-title":"Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp","volume":"45","author":"Kaye","year":"2001","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","article-title":"Bacteraemia in febrile neutropenic cancer patients","volume":"30 Suppl 1","author":"Klastersky","year":"2007","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00000441-198401000-00004","article-title":"A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies","volume":"287","author":"Lawson","year":"1984","journal-title":"American Journal of Medical Sciences"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2796.1998.00379.x","article-title":"The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection","volume":"244","author":"Leibovici","year":"1998","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0133|cit133","first-page":"EPUB","article-title":"Excess mortality related to Cefepime: Comment on the FDA review process and conclusions","volume":"Accepted for pu","author":"Leibovici","year":"2010","journal-title":"Lancet Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jac\/dkh057","article-title":"Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase","volume":"53","author":"Li","year":"2004","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1002\/jhm.408","article-title":"Cefepime: An underrecognized cause of nonconvulsive status epilepticus","volume":"5","author":"Lichaa","year":"2010","journal-title":"Journal of Hospital Medicine"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1007\/s00277-003-0764-4","article-title":"Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society)","volume":"82 Suppl 2","author":"Link","year":"2003","journal-title":"Annals of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0137|cit137","first-page":"181","article-title":"[Cefepime-induced encephalopathy in patients with renal failure]","volume":"29","author":"Martin Herrera","year":"2009","journal-title":"Nefrologia"},{"issue":"9128","key":"10.1002\/14651858.CD005197.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD005197.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clinical infectious Diseases"},{"issue":"7399","key":"10.1002\/14651858.CD005197.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bmj.326.7399.1111","article-title":"Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis","volume":"326","author":"Paul","year":"2003","journal-title":"BMJ"},{"issue":"Issue 3","key":"10.1002\/14651858.CD005197.pub3-BIB0141|cit141","article-title":"Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia","author":"Paul","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jac\/dki028","article-title":"Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Paul","year":"2005","journal-title":"Journal of Antimicrobical Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0143|cit143","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003914.pub2","article-title":"Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients","author":"Paul","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD005197.pub3-BIB0144|cit144","first-page":"424","article-title":"The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004","volume":"9","author":"Paul","year":"2007","journal-title":"Israeli Medical Association Journal"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/29.5.563","article-title":"Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model","volume":"29","author":"Pechere","year":"1992","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0732-8893(97)00064-3","article-title":"Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE)","volume":"28","author":"Pfaller","year":"1997","journal-title":"Diagnostic Microbiology and Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD005197.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","article-title":"Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement","volume":"295","author":"Piaggio","year":"2006","journal-title":"Journal of the Americal Medical Association"},{"issue":"8","key":"10.1002\/14651858.CD005197.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10096-007-0320-6","article-title":"Sources and outcome of bloodstream infections in cancer patients: the role of central venous catheters","volume":"26","author":"Raad","year":"2007","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jac\/dkl193","article-title":"Comment on: empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials","volume":"58","author":"Rolston","year":"2006","journal-title":"Journal of Antimicrobical Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkl349","article-title":"Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units","volume":"58","author":"Roos","year":"2006","journal-title":"The Journal of Antimicrobial cChemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/infdis\/164.5.907","article-title":"Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis","volume":"164","author":"Sanders","year":"1991","journal-title":"Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0152|cit152","first-page":"369","article-title":"Cefepime: the next generation?","volume":"17","author":"Sanders","year":"1993","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/clinids\/23.3.454","article-title":"Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species","volume":"23","author":"Sanders","year":"1996","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Jama"},{"issue":"6","key":"10.1002\/14651858.CD005197.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/AAC.47.6.1882-1886.2003","article-title":"Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species","volume":"47","author":"Schwaber","year":"2003","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD005197.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1179\/joc.2009.21.4.452","article-title":"Cefepime-associated status epilepticus in an ICU patient with renal failure","volume":"21","author":"Shaheen","year":"2009","journal-title":"Journal of Chemotherapy"},{"issue":"8043","key":"10.1002\/14651858.CD005197.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(77)90779-6","article-title":"Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia","volume":"2","author":"Storring","year":"1977","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005197.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.ijantimicag.2005.08.001","article-title":"Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group","volume":"Suppl 2","author":"Tamura","year":"2005","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12028-008-9166-8","article-title":"Cefepime-induced nonconvulsive status epilepticus: case report and review","volume":"10","author":"Thabet","year":"2009","journal-title":"Neurocritical care"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.diagmicrobio.2009.02.008","article-title":"Factors associated with mortality in bacteremic patients with hematologic malignancies","volume":"64","author":"Tumbarello","year":"2009","journal-title":"Diagnostic Microbiology and Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD005197.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10096-003-0894-6","article-title":"Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center","volume":"22","author":"Velasco","year":"2003","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005197.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Diseases"},{"issue":"2","key":"10.1002\/14651858.CD005197.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jac\/dki448","article-title":"Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials","volume":"57(2)","author":"Paul","year":"2006","journal-title":"Journal of Antimicrobial Chemothereapy"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005197.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T18:35:55Z","timestamp":1697222155000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005197.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,11,10]]},"references-count":163,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005197.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,10]]}}}